Trial · NCT03258593
Adverse events261
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 261
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain | Gastrointestinal disorders | Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg | 1 | 12 | 1 |
| other | Abdominal pain | Gastrointestinal disorders | Expansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg | 0 | 3 | 0 |
| other | Abdominal pain | Gastrointestinal disorders | Total Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg | 1 | 15 | 1 |
| other | Allergic rhinitis | Respiratory, thoracic and mediastinal disorders | Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg | 2 | 12 | 2 |
| other | Allergic rhinitis | Respiratory, thoracic and mediastinal disorders | Expansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg | 0 | 3 | 0 |
| other | Allergic rhinitis | Respiratory, thoracic and mediastinal disorders | Total Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg | 2 | 15 | 2 |
| other | Anxiety | Psychiatric disorders | Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg | 1 | 12 | 1 |
| other | Anxiety | Psychiatric disorders | Expansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg | 0 | 3 | 0 |
| other | Anxiety | Psychiatric disorders | Total Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg | 1 | 15 | 1 |
| other | Atrial fibrillation | Cardiac disorders | Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg | 2 | 12 | 3 |
| other | Atrial fibrillation | Cardiac disorders | Expansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg | 0 | 3 | 0 |
| other | Atrial fibrillation | Cardiac disorders | Total Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg | 2 | 15 | 3 |
| other | Atrial flutter | Cardiac disorders | Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg | 1 | 12 | 1 |
| other | Atrial flutter | Cardiac disorders | Expansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg | 0 | 3 | 0 |
| other | Atrial flutter | Cardiac disorders | Total Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg | 1 | 15 | 1 |
| other | Bladder infection | Infections and infestations | Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg | 2 | 12 | 2 |
| other | Bladder infection | Infections and infestations | Expansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg | 0 | 3 | 0 |
| other | Bladder infection | Infections and infestations | Total Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg | 2 | 15 | 2 |
| other | Bladder spasm | Renal and urinary disorders | Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg | 2 | 12 | 2 |
| other | Bladder spasm | Renal and urinary disorders | Expansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg | 0 | 3 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03258593/events